<DOC>
	<DOCNO>NCT02546869</DOCNO>
	<brief_summary>This multi-center , single-arm study design evaluate clinical experience participant ( caregiver ) administer lebrikizumab home participant asthma . Eligible participant receive four dos subcutaneous ( SC ) lebrikizumab every 4 week ( q4w ) Week 12 . Primary analysis visit occur Week 13 . After study treatment , participant complete 12 week safety follow . All participant get train administartion lebrikizumab use device .</brief_summary>
	<brief_title>A Single-Arm Study Evaluate Administration Lebrikizumab Participants Caregivers Home Setting</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age 18 75 year Week 1 Asthma diagnosis great equal ( &gt; = ) 12 month prior Week 1 Prebronchodilator force expiratory volume 1 second ( FEV1 ) &gt; =40 % predict Week 1 Week 0 ( Day 1 ; prior enter treatment phase ) , base establish spirometry reference equation Competent willing , determined investigator , independently administer lebrikizumab home . The investigator need confirm participant ( caregiver ) able follow instruction administer lebrikizumab Able willing take home prefilled syrinx lebrikizumab conclusion Week 0 ( Day 1 ) store accord requirement highlight within Instructions Use ( IFU ) document . History severe allergic reaction anaphylactic reaction biologic agent know hypersensitivity component lebrikizumab injection Hospitalization reason , include acute exacerbation event , within 4 week prior Week 1 screening period Infection require hopitalization , treatment intravenous ( IV ) intramuscular antibiotic within 4 week oral antibiotic within 2 week prior Week 1 screen Taken part previous clinical trial lebrikizumab discontinue trial prematurely discontinue study drug prematurely due adverse event</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>